biotech / news / / MarketScreener
The European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI.
The European Commission approved HYMPAVZI for hemophilia A or B patients 12+ with FVIII or FIX inhibitors.
KEY POINTS
- HYMPAVZI reduced mean treated annualized bleeding rate by 93% in Phase 3 BASIS trial.
- HYMPAVZI is the first anti-TFPI approved for hemophilia and the first via pre-filled auto-injector pen.
- HYMPAVZI’s mechanism targets TFPI, not replacement factors, offering an alternative for inhibitor patients.
- For hemophilia B, HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment option.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →